Scleroderma (systemic sclerosis) is a multisystem disorder which can often be confined to the connective tissues outside the major organ systems. The morbidity, and ultimately the mortality, risk from scleroderma stems, however, from the possible involvement of the lungs, heart, or kidneys. The disease itself is rare and often fatal when one of a number of different combinations of internal organs is affected. As a consequence, overall survival rate is a useful measure of outcome, which can be applied across groups of patients in studies of natural history. This is different from the situation with other connective tissue disorders, such as systemic lupus erythematosus, which have a relatively low mortality' and for which other outcome indicators are more appropriate.2 3 The other advantages of adopting survival as the standard measure of outcome are the relative ease of obtaining mortality data and the standardisation in data collection between centres.
There are a number of problems in interpreting survival data from the various centres. Firstly, as mentioned above, scleroderma is a rare disease with an annual incidence of under 10 per million population in both the United Kingdom4 and other countries. 5 18 19 It is also apparent from the data that even limited skin disease at presentation is associated with a high mortality risk and that this risk increases with time. A recent small study found that the extent of skin sclerosis did not explain the mortality risk at five years,'7 but this result is at odds with the experience of others.
SCLEROSIS IN OTHER ORGANS
There is absolutely no doubt that sclerosis of the kidneys, lung, or heart is a bad prognostic sign. In one large study of 646 patients from Pittsburgh none of the 24 patients with kidney disease at onset survived for six years, and even the one year survival was only 25%. 21 Similarly, those with the heart affected, in the absence of kidney disease, had a three year survival of 50% and none survived for more than nine years. By contrast, the presence of isolated lung disease was consistent with a 10 year survival of over 50% and those with none of these major organ systems affected had a 10 year survival of 70%. Numerous other studies report similar findings.7 13 It is perhaps too early to judge whether the advent of the use of angiotensin converting enzyme inhibitors for the treatment of scleroderma renal crisis will improve the prognosis from scleroderma kidney disease, but this therapeutic advance seems the only likely possibility of substantially altering mortality.25 OTHER 
MARKERS
There have been two reports suggesting that anaemia is a bad prognostic sign9 13 which may be independent of any renal effect on blood. Similarly, there have been a number of studies suggesting that the erythrocyte sedimentation rate at presentation is a predictor of future mortality,9 1317 with a rise as modest as 32 being important. Others have found no effect on mortality of the sedimentation rate or other serum markers, including antinuclear antibody positivity and immunoglobulin concentra- There have been some interesting suggestions of specific cancer risks with scleroderma. One report of an unexpected cluster of breast cancer cases in women with scleroderma28 was followed by a formal epidemiology study that could not confirm an excess of breast cancer but did suggest a temporal relation between the onset of the two diseases in some women. 29 More relevant in that study was the increased rate of lung cancer in patients with scleroderma. This seems to be independent of cigarette smoking but related to the presence of pulmonary fibrosis.30 This is perhaps not a surprising result given the association of lung cancer with pulmonary fibrosis from occupational causes. Thus it is perhaps likely that part of the excess mortality from scleroderma is not only primarily attributable to the scleroderma but also due to secondary associated pathological changes, though the exact magnitude of any increased risk in 'unrelated' deaths is unknown.
Conclusion
Scleroderma has a high excess mortality, which continues over time for at least 15 years. The magnitude and continuing time course of this excess mortality are similar to those noted in some cancers, such as that of the breast. Survival has altered little in the past 50 years, which might reflect the lack of any treatment that has been shown to improve prognosis. The extent of skin sclerosis, although an imperfect marker, is perhaps the best current guide to future prognosis.
